Conformational landscape of selective μ-opioid agonists in gas phase and in aqueous solution: The fentanyl series

Govindan Subramanian, David M. Ferguson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The conformational characteristics responsible for high affinity μ-opioid of a series of fentanyl analogs have been investigated using a combination of molecular mechanics and molecular dynamics techniques. In general, the fentanyl analogs favor a conformation that is quite different in gas phase, and in the presence of explicit solvent or lattice packing forces. The most active analogs were shown to possess an extended conformation, while fentanyl derivatives displaying reduced binding affinities are predicted to favor compact arrangements. A superposition of the proposed 'bioactive conformations' across this ligand series identified the orientation of the N-phenethyl and the N-phenyl group to be a contributing factor responsible for the differential binding of the ohmefentanyl enantiomers, and other structural analogs. The proposed 3-point pharmacophore model for the fentanyls also provide insights into the structure-activity relationship and serve as a template for further QSAR and docking studies.

Original languageEnglish (US)
Pages (from-to)55-67
Number of pages13
JournalDrug Design and Discovery
Volume17
Issue number1
StatePublished - Jul 8 2000

Fingerprint

Fentanyl
Opioid Analgesics
Gases
Quantitative Structure-Activity Relationship
Molecular Dynamics Simulation
Structure-Activity Relationship
Mechanics
Ligands

Keywords

  • Bioactive conformation
  • Fentanyl
  • MD simulations
  • Opioid ligands
  • Pharmacophore
  • μ-Agonists

Cite this

Conformational landscape of selective μ-opioid agonists in gas phase and in aqueous solution : The fentanyl series. / Subramanian, Govindan; Ferguson, David M.

In: Drug Design and Discovery, Vol. 17, No. 1, 08.07.2000, p. 55-67.

Research output: Contribution to journalArticle

@article{eecd00ed0a4343ea876e835b41527bff,
title = "Conformational landscape of selective μ-opioid agonists in gas phase and in aqueous solution: The fentanyl series",
abstract = "The conformational characteristics responsible for high affinity μ-opioid of a series of fentanyl analogs have been investigated using a combination of molecular mechanics and molecular dynamics techniques. In general, the fentanyl analogs favor a conformation that is quite different in gas phase, and in the presence of explicit solvent or lattice packing forces. The most active analogs were shown to possess an extended conformation, while fentanyl derivatives displaying reduced binding affinities are predicted to favor compact arrangements. A superposition of the proposed 'bioactive conformations' across this ligand series identified the orientation of the N-phenethyl and the N-phenyl group to be a contributing factor responsible for the differential binding of the ohmefentanyl enantiomers, and other structural analogs. The proposed 3-point pharmacophore model for the fentanyls also provide insights into the structure-activity relationship and serve as a template for further QSAR and docking studies.",
keywords = "Bioactive conformation, Fentanyl, MD simulations, Opioid ligands, Pharmacophore, μ-Agonists",
author = "Govindan Subramanian and Ferguson, {David M.}",
year = "2000",
month = "7",
day = "8",
language = "English (US)",
volume = "17",
pages = "55--67",
journal = "Drug Design and Discovery",
issn = "1055-9612",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Conformational landscape of selective μ-opioid agonists in gas phase and in aqueous solution

T2 - The fentanyl series

AU - Subramanian, Govindan

AU - Ferguson, David M.

PY - 2000/7/8

Y1 - 2000/7/8

N2 - The conformational characteristics responsible for high affinity μ-opioid of a series of fentanyl analogs have been investigated using a combination of molecular mechanics and molecular dynamics techniques. In general, the fentanyl analogs favor a conformation that is quite different in gas phase, and in the presence of explicit solvent or lattice packing forces. The most active analogs were shown to possess an extended conformation, while fentanyl derivatives displaying reduced binding affinities are predicted to favor compact arrangements. A superposition of the proposed 'bioactive conformations' across this ligand series identified the orientation of the N-phenethyl and the N-phenyl group to be a contributing factor responsible for the differential binding of the ohmefentanyl enantiomers, and other structural analogs. The proposed 3-point pharmacophore model for the fentanyls also provide insights into the structure-activity relationship and serve as a template for further QSAR and docking studies.

AB - The conformational characteristics responsible for high affinity μ-opioid of a series of fentanyl analogs have been investigated using a combination of molecular mechanics and molecular dynamics techniques. In general, the fentanyl analogs favor a conformation that is quite different in gas phase, and in the presence of explicit solvent or lattice packing forces. The most active analogs were shown to possess an extended conformation, while fentanyl derivatives displaying reduced binding affinities are predicted to favor compact arrangements. A superposition of the proposed 'bioactive conformations' across this ligand series identified the orientation of the N-phenethyl and the N-phenyl group to be a contributing factor responsible for the differential binding of the ohmefentanyl enantiomers, and other structural analogs. The proposed 3-point pharmacophore model for the fentanyls also provide insights into the structure-activity relationship and serve as a template for further QSAR and docking studies.

KW - Bioactive conformation

KW - Fentanyl

KW - MD simulations

KW - Opioid ligands

KW - Pharmacophore

KW - μ-Agonists

UR - http://www.scopus.com/inward/record.url?scp=0034088315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034088315&partnerID=8YFLogxK

M3 - Article

C2 - 10928449

AN - SCOPUS:0034088315

VL - 17

SP - 55

EP - 67

JO - Drug Design and Discovery

JF - Drug Design and Discovery

SN - 1055-9612

IS - 1

ER -